ETF Managers Group’s ARS Pharmaceuticals SPRY Stock Holding History

ETF Managers Group’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$207K	Buy	31,789 +7,998	+34%	+$61.4K	0.01%	581
2022 Q4	$203K	Buy	23,791 +13,323	+127%	+$86.4K	0.01%	476
2022 Q3	$55K	Sell	10,468 -636	-6%	-$3.13K	﹤0.01%	668
2022 Q2	$49K	Buy	11,104 +464	+4%	+$1.62K	﹤0.01%	710
2022 Q1	$37K	Buy	10,640 +35	+0.3%	+$152	﹤0.01%	669
2021 Q4	$70K	Sell	10,605 -1,204	-10%	-$9.78K	﹤0.01%	652
2021 Q3	$125K	Buy	11,809 +1,514	+15%	+$37.3K	﹤0.01%	632
2021 Q2	$325K	Sell	10,295 -431	-4%	-$13.8K	0.01%	583
2021 Q1	$435K	Buy	+10,726	New	+$508K	0.01%	511

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $947M AUM 29.56% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return